Hepalink
VC Fund
Shenzhen, China
Hepalink is a VC fund in Shenzhen focused on Biopharma and Therapeutics. Hepalink was established in 1998 and restructured in 2007 to be a limited liability company. Hepalink went public and was listed on the Shenzhen Stock Exchange on May 6, 2010 (stock code "002399"). Hepalink’s headquarters are located in the Shenzhen High-Tech Park.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Hepalink invests in
Stages Hepalink invests in
Countries Hepalink invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bruce Wendel
|
|||
|
Frank Sun
|
|||
|
Kong Yun
|
|||
Shawn Lu
|
|||
Investment Focus
Industry
- Biopharma 2 (100%)
- Therapeutics 2 (100%)
- Biotechnology 2 (100%)
- Health Care 1 (50%)
Stage
- Series C 1 (50%)
- Post-IPO Debt 1 (50%)
Country
- Canada 1 (50%)
- United Kingdom 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bruce Wendel
Chief Strategy Officer
|
Chief Strategy Officer | Total investments: 0 | Find email | |
|
Frank Sun
Executive Director & Vice Chairman
|
Executive Director & Vice Chairman | Total investments: 0 | Find email | |
|
Kong Yun
CFO
|
CFO | Total investments: 0 | Find email | |
|
Shawn Lu
CFO, Director
|
CFO, Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Resverlogix
|
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial inhumans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular diseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada. | $6M / Post-IPO Debt / May 05, 2021 | |
Kymab
|
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making themthe most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom. | $100M / Series C / Nov 24, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hepalink invest in?
Hepalink invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series C and Post-IPO Debt stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hepalink?
Public channels for Hepalink include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hepalink?
The team at Hepalink includes Bruce Wendel (Chief Strategy Officer), Frank Sun (Executive Director & Vice Chairman) and Kong Yun (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
